Consistently, the serum contents of pro‐inflammatory cytokines, hepatic function indicators, activated liver Zdhhc3, and a significant increase in pan‐palmitoylation contents along with Irhom2‐Map3k7 signaling axis were markedly suppressed by dose‐dependent 2‐BP treatment in the context of NASH (Figure S18c–f, Supporting Information). This evidence concerns the gene RHBDF2 and metabolic dysfunction-associated steatohepatitis.